Coagulation defects.
The present understanding of the coagulation process emphasizes the final common pathway and the proteolytic systems that result in the degradation of formed clots and the prevention of unwanted clot formations, as well as a variety of defense systems that include tissue repair, autoimmune processes, arteriosclerosis, tumor growth, the spread of metastases, and defense systems against micro-organisms. This article discusses diagnosis and management of some of the most common bleeding disorders. The goals are to provide a simple guide on how best to manage patients afflicted with congenital or acquired clotting abnormalities during the perioperative period, present a brief overview of the methods of testing and monitoring the coagulation defects, and discuss the appropriate pharmacologic or blood component therapies for each disease.
Soliman
Doreen E
DE
Division of Pediatric Anesthesiology, University of Pittsburgh Medical Center and Children's Hospital of Pittsburgh, 3705 Fifth Avenue, Pittsburgh, PA 15213, USA. solimande@anes.upmc.edu
Broadman
Lynn M
LM
D000758:Anesthesia; D015415:Biomarkers / Q000032:analysis; D001777:Blood Coagulation / Q000502:physiology; D001778:Blood Coagulation Disorders / Q000097:blood* / Q000151:congenital / Q000628:therapy; D001779:Blood Coagulation Factors / Q000037:antagonists & inhibitors* / Q000276:immunology; D001780:Blood Coagulation Tests; D016063:Blood Loss, Surgical / Q000517:prevention & control; D006801:Humans; D019990:Perioperative Care; D013514:Surgical Procedures, Operative
D015415:Biomarkers; D001779:Blood Coagulation Factors